<DOC>
	<DOCNO>NCT00053183</DOCNO>
	<brief_summary>RATIONALE : Internal radiation use radioactive material place directly near tumor kill tumor cell . External-beam radiation therapy use high-energy x-ray kill tumor cell . Combining internal radiation external-beam radiation therapy may kill remain tumor cell follow surgery . PURPOSE : Phase I trial study effectiveness combine internal radiation therapy external-beam radiation therapy treat patient undergone surgery glioblastoma multiforme .</brief_summary>
	<brief_title>Surgery Followed Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose brachytherapy administer via GliaSite RTS™ applicator follow external beam radiotherapy patient newly diagnose glioblastoma multiforme . - Determine acute chronic toxicity brachytherapy administer via GliaSite RTS™ patient . - Determine survival rate patient treat regimen . OUTLINE : This multicenter , dose-escalation study brachytherapy . Patients undergo craniotomy histologic confirmation glioblastoma multiforme , surgical resection , placement GliaSite RTS™ applicator include Iotrex™ . Beginning 3-21 day surgery , patient undergo brachytherapy via GliaSite RTS™ applicator . Within 30 day brachytherapy ( 60 day resection ) patient undergo external beam radiotherapy 5 day week 6 week absence disease progression unacceptable toxicity . Cohorts 5-10 patient receive escalate dos brachytherapy maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 5 3 10 patient experience dose-limiting toxicity . Patients follow 21-35 day , every 2 month 1 year , survival . PROJECTED ACCRUAL : A total 15-100 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Clinically suspect supratentorial grade IV glioblastoma multiforme Candidate maximal surgical resection tumor mass Expected residual enhance tumor must within expect brachytherapy treatment volume Resection must expect result new permanent neurologic deficit No clearly multifocal disease ( 2 separate focus contrastenhancing tumor within expect brachytherapy prescription volume MRI ) No enhance tumor great 1 cm beyond midline MRI No grossly radiographically apparent leptomeningeal spread and/or ventricular invasion outside anticipated radiation treatment volume No mark edema MRI significant shift anticipate corrected resection PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Not specify Renal Creatinine great 1.7 mg/dL BUN great 2 time upper limit normal Cardiovascular No uncontrolled hypertension No unstable angina pectoris No uncontrolled cardiac dysrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Mini mental state exam score least 15 No concurrent medical illness would preclude study participation No concurrent serious infection No malignancy within past 5 year except curatively treat carcinoma situ cervix nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No immunotherapy prior , , within 90 day brachytherapy No biologic therapy follow prior , , within 90 day brachytherapy : Immunotoxins Immunoconjugates Antiangiogenesis compound Peptide receptor antagonist Interferons Interleukins Tumorinfiltrating lymphocyte Lymphokineactivated killer cell Gene therapy Antisense agent Chemotherapy No chemotherapy polifeprosan 20 carmustine implant ( Gliadel wafer ) prior , , within 90 day brachytherapy Endocrine therapy No hormonal therapy prior , , within 90 day brachytherapy Concurrent corticosteroid improve quality life allow Radiotherapy No radiotherapy prior , , within 90 day brachytherapy Surgery See Disease Characteristics No radiosurgery prior , , within 90 day brachytherapy Other No investigational agent direct brain tumor prior , , within 90 day brachytherapy Concurrent noncytotoxic therapy improve quality life allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>